-
April 15, 2013
Drugmakers have attacked US President Barack Obama's proposed FY 2014 budget, which would require them to pay increased Medicare drug rebates and ban "pay for delay" deals between brand-name and generics firms.
Full story
-
April 03, 2013
President Obama has unveiled the BRAIN Initiative, which the White House describes as "a bold new research effort to revolutionise our understanding of the human mind"
Full story
-
May 16, 2012
The US government has unveiled what it describes as ambitious plans to fight Alzheimer’s disease, including the development of effective prevention and treatments by 2025
Full story
-
February 22, 2012
The US Food and Drug Administration has stepped in to increase the supply of critically-needed cancer drugs, specifically shortages of Johnson & Johnson's Doxil and methotrexate, caused by manufacturing problems at Ben Venue Laboratories
Full story
-
February 14, 2012
Drugmakers have declared their profound disappointment with President Barack Obama's budget proposals for healthcare, saying they threaten jobs and innovation
Full story
-
November 13, 2011
New US Congressional estimates say that banning "pay-for-delay" deals would cut the federal deficit by $4.8 billion over 10 years; last year it had put the savings at about $2.6 billion.
Full story
-
April 15, 2011
President Barack Obama has pledged to use the purchasing power of Medicare to "limit unnecessary prescription drug spending,” speed the availability of generic drugs and ban "pay-for-delay" agreements.
Full story
-
March 25, 2011
50% discounts on prescription drugs costs agreed by drugmakers and introduced at the start of the year have saved seniors enrolled in Medicare $38 million in just two months, the US government has announced.
Full story
-
March 10, 2011
The pharmaceutical industry has warmly greeted the news that the US Senate has voted to change the country's patent laws which have largely remained untouched since the 1950s
Full story
-
February 15, 2011
Innovation-based drugmakers have told President Obama in no uncertain they are not impressed by his 2012 budget proposals, especially plans to reduce patent protection on biologics and end 'pay-for-delay' deals with generics firms
Full story